Aspiriant LLC Has $617,000 Position in Novo Nordisk A/S (NYSE:NVO)

Aspiriant LLC lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,806 shares of the company’s stock after selling 384 shares during the quarter. Aspiriant LLC’s holdings in Novo Nordisk A/S were worth $617,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Pacific Center for Financial Services raised its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the period. First PREMIER Bank acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth approximately $25,000. CNB Bank bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $26,000. Tyler Stone Wealth Management grew its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. grew its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $144.51 on Friday. The firm’s 50 day simple moving average is $134.16 and its 200 day simple moving average is $122.88. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $648.49 billion, a PE ratio of 49.83, a price-to-earnings-growth ratio of 1.43 and a beta of 0.41. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The company had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, analysts expect that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on NVO. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 price objective on shares of Novo Nordisk A/S in a research note on Tuesday. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, June 17th. Finally, Argus lifted their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.